News - Immunologicals


Current filters:


Popular Filters

90 to 114 of 129 results

News briefs: setbacks for B-MS hep C drug; Baxter's HyQ


US drug major Bristol-Myers Squibb (NYSE: BMY) has suspended study drug administration in ongoing Phase…

Anti-viralsBaxter InternationalBMS-986094Bristol-Myers SquibbHyQImmunologicalsNorth AmericaPharmaceuticalRegulationResearch

ALK Abello partner Torii progresses Japanese development of Mitizax


Denmark-based allergy specialist ALK Abello (ALKB: DC) revealed yesterday that its strategic partner,…

ALK AbelloImmunologicalsMitizaxPharmaceuticalResearchRespiratory and PulmonaryTorii Pharma

Barriers to overcome in lupus drug development


It has taken the lupus research community over 50 years to produce a new therapy. Although it is now…

Anthera PharmaceuticalsBenlystaBiotechnologyblisibimodGlaxoSmithKlineImmunologicalsPharmaceuticalResearch

Rapamycin raises cognition throughout life span, study in mice shows


Cognitive skills such as learning and memory diminish with age in everyone, and the drop-off is steepest…


Positive interim clinical data in allergic children treated with Viaskin Peanut


French allergy specialist DBV Technologies (Euronext: DBV), creator of Viaskin, a new standard in the…

DBV TechnologiesImmunologicalsPharmaceuticalResearchViaskin

Osiris gets second approval for Prochymal, in New Zealand


USA-based Osiris Therapeutics (Nasdaq: OSIR) has received a second approval to market its first-in-class…

Asia-PacificBiotechnologyImmunologicalsOsiris TherapeuticsProchymalRegulation

Positive long-term results for Bristol-Myers Squibb's Nulojix in organ rejection


US drug major Bristol-Myers Squibb (NYSE: BMY) yesterday presented the data at the 2012 American Transplant…

Bristol-Myers SquibbImmunologicalsNulojixPharmaceuticalResearch

InterMune to divest Actimmune for $55 million; to focus on Esbriet


California, USA-based biotech firm InterMune (Nasdaq: ITMN) says that it has reached a definitive agreement…

ActimmuneBiotechnologyEsbrietFinancialImmunologicalsInterMuneMergers & AcquisitionsRespiratory and PulmonaryVidara Therapeutics

World's first stem cell drug, Osiris' Prochymal, approved in Canada


USA-based Osiris Therapeutics (Nasdaq: OSIR) has received market authorization from Health Canada to…

BiotechnologyImmunologicalsNorth AmericaOsiris TherapeuticsProchymalRegulation

Cell Therapeutics to acquire pacritinib, a potential myelofibrosis drug


US biotech firm Cell Therapeutics (Nasdaq and MTA: CTIC) and Singapore-based S*BIO Pte have entered into…

BiotechnologyCell TherapeuticsImmunologicalsLicensingOncologypacritinibS*BIO

Halozyme plunges as FDA call for more data on HyQ BLA


USA-based Halozyme Therapeutics saw its shares plummet 24% to $8.56 by close of trading yesterday, after…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQImmunologicalsNorth AmericaRegulation

GlaxoSmithKline links with Japan's Chiome on MAbs


UK pharma giant GlaxoSmithKline group (LSE: GSK) and Tokyo, Japan-based biotech-venture company Chiome…

BiotechnologyChiome BioscienceGlaxoSmithKlineImmunologicalsLicensingOncologyPharmaceuticalResearch

Novartis expands transplant portfolio with first branded generic tacrolimus


Swiss drug major Novartis has announced the US introduction and availability of Hecoria (tacrolimus)…

Astellas PharmaGenericsHecoriaImmunologicalsMarkets & MarketingNorth AmericaNovartisPrografSandoztacrolimus

Recalls threaten public confidence in vaccines and immunoglobulins


Quality defects and donor tissue history must be more carefully monitored to increase public acceptance…


Ablynx extends Nanobody deal with Boehringer


Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

FDA calls for more data on Merck combo drug; Good results with allergy drug


The US Food and Drug Administration (FDA) has issued a Complete Response Letter to drug giant Merck &…

ALK AbelloatorvastatinCardio-vascularezetimibeImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulationResearch

Sanofi surprises Osiris by pulling out of Prochymal deal


Maryland, USA-based Osiris Therapeutics (Nasdaq: OSIR) has provided an update on the status of the development…

GenzymeImmunologicalsLicensingOsiris TherapeuticsPharmaceuticalProchymalSanofi

Otsuka Pharma and UCB re-focus collaboration


Japan’s Otsuka Pharmaceutical (TYO: 4768) and Belgian drugmaker UCB (Euronext Brussels: UCB) have…


FDA gives Hemispherx time to respond to CRL


Shares of USA-based Hemispherx Biopharma (NYSE Amex: HEB) rose 14% to $0.24 on Wednesday, after the company…

AmpligenHemispherx BioPharmaImmunologicalsNorth AmericaPharmaceuticalRegulation

UCB and Immunomedics amend epratuzumab accord


New Jersey, USA-based Immunomedics (Nasdaq: IMMU) and Belgian drugmaker UCB (Euronext Brussels: UCB)…

epratuzumabImmunologicalsImmunomedicsLicensingPharmaceuticalRare diseasesUCB

Karo Bio skyrockets on deal with Pfizer


Sweden’s Karo Bio (STO: KARO) saw its shares rocket 80% to 1.67 Swedish ronor on December 24, after…

Anti-Arthritics/RheumaticsImmunologicalsKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Ablynx earns milestone from Merck Serono


Belgium’s Ablynx (Euronext Brussels: ABLX) says it will earn a 1 million-euro ($1.3 million) from…

AblynxBiotechnologyFinancialImmunologicalsMerck KGaAMerck SeronoPharmaceuticalResearch

Number of monoclonal antibody products in development continues to increase, says Tufts CSDD


Developers are steadily increasing the number of monoclonal antibody products - known as MAbs - for which…


EMA says risk-benefit of ARBs positive; acts on Advagraf and Protelos/Osseor


In a flurry of late news yesterday from the European Medicines Agency and its Committee for Medicinal…

AdvagrafAnti-Arthritics/RheumaticsAstellas PharmaCardio-vascularEuropeImmunologicalsPharmaceuticalProtelosRegulationServier

90 to 114 of 129 results

Back to top